Biotech bites: Sirtex to be listed on S&P/ASX 200
Tuesday, 18 December, 2012
Anti-cancer company Sirtex Medical (ASX:SRX) has received a Christmas treat by being slated to be listed on the S&P/ASX 200 index.
This follows the removal of Integra Mining Limited (ASX:IGR) from the list by S&P Dow Jones Indices, pending approval of the merger of Integra with Silver Lake Resources (ASX:SLR).
Sirtex will join the S&P/ASX 200 after the close of trading on 24 December 2012, just as Santa is hefting his sack on to his sleigh.
Sirtex Medical specialises in SIR-Spheres microspheres, which are a medical device used to treat liver cancer by delivering Selective Internal Radiation Therapy (SIRT) to the liver.
Sales of SIR-Sphere have been growing, particularly in the United States and the Asia Pacific region.
The company's share price (ASX:SRX) jumped 5% during the day's trading, up 6c to $12.75. This time last year they were changing hands for $4.34.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
